Dacomitinib Patent Expiration
Dacomitinib is used for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. It was first introduced by Pfizer Inc
Dacomitinib Patents
Given below is the list of patents protecting Dacomitinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vizimpro | US7772243 | 4-phenylamino-quinazolin-6-yl-amides | Sep 27, 2032 | Pfizer |
| Vizimpro | US10596162 | Method for treating gefitinib resistant cancer |
Feb 02, 2026
(Expired) | Pfizer |
| Vizimpro | US10603314 | Method for treating gefitinib resistant cancer |
Feb 02, 2026
(Expired) | Pfizer |
| Vizimpro | US8623883 | 4-phenylamino-quinazolin-6-yl-amides |
May 05, 2025
(Expired) | Pfizer |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Dacomitinib's patents.
Latest Legal Activities on Dacomitinib's Patents
Given below is the list recent legal activities going on the following patents of Dacomitinib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent | 09 Feb, 2026 | US8623883 |
| Patent Term Extension Certificate | 26 Nov, 2025 | US7772243 |
| Patent Term Extension Certificate | 14 Nov, 2025 | US7772243 |
| Maintenance Fee Reminder Mailed | 25 Aug, 2025 | US8623883 |
| Notice of Final Determination -Eligible | 09 May, 2025 | US7772243 |
| Notice of Final Determination -Eligible | 31 Jan, 2025 | US7772243 |
| FDA Final Eligibility Letter | 13 Jan, 2025 | US7772243 |
| transaction for FDA Determination of Regulatory Review Period | 28 Dec, 2023 | US7772243 |
| transaction for FDA Determination of Regulatory Review Period | 08 Dec, 2023 | US7772243 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Sep, 2023 | US10603314(Litigated) |
Dacomitinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Dacomitinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study | Region Skane | NA |
RECRUITING
(May 1, 2026)
| PHASE3 |
| HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease | MedSIR | NA |
COMPLETED
(Apr 1, 2026)
| PHASE2 |